Research programme: anti-viral therapy - Invirsa

Drug Profile

Research programme: anti-viral therapy - Invirsa

Alternative Names: INV-102

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Invirsa
  • Class Adenine nucleotides; Anti-infectives; Anti-inflammatories; Antivirals; Eye disorder therapies; Small molecules
  • Mechanism of Action DNA repair enzyme stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Keratoconjunctivitis
  • Research Respiratory tract infections

Most Recent Events

  • 07 Nov 2017 Early research in Respiratory tract infections in USA (unspecified route)
  • 07 Nov 2017 Preclinical trials in Keratoconjunctivitis in USA (Topical)
  • 07 Nov 2017 Pharmacodynamics data from a preclinical trial in keratoconjunctivitis released by Invirsa (Invirsa website, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top